<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1592">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086148</url>
  </required_header>
  <id_info>
    <org_study_id>2017-03-16</org_study_id>
    <nct_id>NCT03086148</nct_id>
  </id_info>
  <brief_title>Ketamine and Postoperative Depressive Symptom</brief_title>
  <official_title>The Effect of Ketamine on Postoperative Depressive Symptom in Patients Undergoing Supratentorial Tumor Resection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative depression symptom is one of the common metal complications which will affect
      patients' clinical outcome and prognosis and it may reduce long-term quality of life (QOL).
      However, there isn't any effective treatment can relieve patients' depression symptom. To
      date, lots of clinical trails have confirmed that low-dose ketamine have robust, rapid, and
      sustained antidepressant properties. The remission of major depressive episodes has proved,
      however the application during perioperative for depression symptom have not researched
      ever. Thus, we need to design a random-controlled clinical trail to observe the
      anti-depression effect during perioperative. If ketamine can reduce the depression symptom
      significantly, this treatment can be popularized in future clinical works to decrease the
      rate of perioperative adverse events related of patients' depressive symptom and to enhance
      the patients' long-term QOL.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression symptom</measure>
    <time_frame>Postoperative 3 days</time_frame>
    <description>Montgomery-Åsberg Depression Rating Scale will be used to assess the depression symptom.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Ketamine; Depression Symptom; Brain Tumor; Outcome</condition>
  <arm_group>
    <arm_group_label>ketamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be administrated at the dose of 0.5 mg/kg intravenously during 40 minutes.</description>
    <arm_group_label>ketamine group</arm_group_label>
    <other_name>Ketamine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline will be administrated at the dose of 0.5 ml/kg intravenously during 40 minutes.</description>
    <arm_group_label>normal saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Elective supratentorial tumor patient

          2. Ages between 18 and 80 years old

          3. Patients with moderate to severe depression symptom screened by MARDS

        Exclusion Criteria:

          1. American Society of Anesthesiologists (ASA) physical status Ⅳ-Ⅴ,

          2. BMI＞30kg/㎡

          3. Systolic blood pressure&gt;180mmHg

          4. Heart Rate&gt;120

          5. Heart failure

          6. History of psychiatric illness

          7. Awake craniotomy surgery

          8. Pregnant or breast-feeding woman

          9. Patient with renal or liver dysfunction

         10. History of drug abuse

         11. Emergency surgery

         12. History of ketamine's adverse reaction

         13. Patient refused to sign the consent

         14. Patient cannot able to complete the scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph.D</last_name>
    <phone>8610-67096660</phone>
    <email>ruquan.han@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing TianTan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-67096660</phone>
      <email>ruquan.han@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>March 16, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yuming Peng</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
